Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5852W HIGH $4.94
Volume
32.62 K
Value Traded
97.73 K
Short % Float
0.55%
Days to Cover
1.0
+10.81%Week
-8.48%1 Month
-22.93%3 Month
-30.74%6 Month
-84.14%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.70 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
-1.78 M
Total Shares
2.29 M
Float Shares
1.98 M
Insiders
15.70%
Institutions
6.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Xenetic Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xenetic Biosciences, Inc.
201Total events
9Upcoming
47Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedTrial
First patient dosed in investigator-initiated study of systemic DNase in combination with CAR T cells for LBCL
Large B-Cell Lymphomasource ↗
▲First Patient DosedTrial
First patient dosed in investigator-initiated study of systemic DNase with anti-CD19 CAR T-cell therapy in LBCL
large B-cell lymphomasource ↗
▲AcquiredCorporate
Xenetic and Santersus enter definitive share exchange agreement for Xenetic to acquire Santersus
◆AbstractPresentation
Abstract accepted for presentation at 2026 ASCO Annual Meeting
Hematologic Malignancies - Plasma Cell Dyscrasiasource ↗
▲Ethics Committee ApprovalTrial
Institutional Review Board approval of investigator-initiated DNase/CAR T study
Large B-Cell Lymphomasource ↗
▲Trial Authorization (CTA / IND)Ex-US Regulatory
Israeli Ministry of Health approval of investigator-initiated DNase/CAR T study
Large B-Cell Lymphomasource ↗
▲Ethics Committee ApprovalTrial
Israeli Ministry of Health and Institutional Review Board approved investigator-initiated DNase/CAR T study
large B-cell lymphomasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma
large B-cell lymphomasource ↗
●Manufacturing MilestoneCMC / Inspection
Completed process improvement and analytical development activities supporting future clinical manufacturing readiness
▲Biomarker DataClinical Data
Generated robust translational data supporting DNase I platform across multiple oncology settings
multiple oncology settingssource ↗
▲Oral PresentationPresentation
Positive preclinical and translational data presented at 2026 ASCO Annual Meeting
hematologic cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
PeriNess Ltd. received approval from Israeli Ministry of Health and IRB to conduct investigator-initiated exploratory study
large B-cell lymphomasource ↗
▼Quarterly UpdateCorporate
2025 Annual Meeting of Stockholders adjourned due to lack of quorum
▼Equity OfferingCorporate
Closed underwritten public offering for net proceeds of approximately $3.9 million
▲Partnership / LicenseCorporate
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and develop program combining systemic DNase I with CAR T-cell therapies
▲Trial InitiationTrial
Entered into Clinical Study Agreement to support exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma
large B cell lymphomasource ↗
▲First Patient DosedTrial
Commenced patient dosing in exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for first-line treatment of unresectable, locally advanced or metastatic pancreatic cancer at Bnei Zion Medical Center
unresectable, locally advanced or metastatic pancreatic cancersource ↗
●Quarterly UpdateCorporate
Reported second quarter 2025 financial results with net loss of $0.7 million and cash of $4.8 million
▲Partnership / LicenseDNaseCorporate
PeriNess Ltd. entered into Clinical Study Agreement for DNase platform in osteosarcoma and Ewing sarcoma
relapsed/refractory osteosarcoma and Ewing sarcomasource ↗
●Preclinical PoCPreclinical
Preliminary preclinical studies of DNase I with chemotherapy and immunotherapy in colorectal cancer models completed
colorectal cancersource ↗
▲Preclinical PoCPreclinical
Completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies and CAR-T approaches
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
▲IND Enabling CompletePreclinical
Progressed toward IND-enabling activities for DNase I program
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
●IND SubmissionIND
IND submission expected for Phase 1 clinical trial
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
●Trial InitiationTrial
Planned Phase 1 clinical trial for DNase I in pancreatic carcinoma
pancreatic carcinomasource ↗
◆Preclinical PoCPreclinical
Preclinical data expected before year end
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
▲Partnership / LicenseDNaseCorporate
Entered into Clinical Trial Services Agreement with PeriNess for exploratory investigator-initiated studies
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
▲Partnership / LicenseCorporate
Extended Research Funding and Option Agreement with The Scripps Research Institute
▲Preclinical PoCPreclinical
Preclinical evaluation of systemic DNase I in combination with CAR-T cells shows reduced tumor burden and prolonged survival
CD19-expressing hematological cancers; EGFR-expressing metastatic melanomasource ↗
●Preclinical PoCPreclinical
Preliminary preclinical studies evaluating DNase I combinations in colorectal cancer models completed
colorectal cancersource ↗
▲Preclinical PoCPreclinical
Encouraging preclinical data for DNase-based oncology platform
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
◆Preclinical PoCDNasePreclinical
Preclinical studies initiated on DNase in combination with chemotherapy or immune checkpoint blockade
solid tumorssource ↗
◆Trial InitiationTrial
Advancement towards Phase 1 clinical study
pancreatic carcinoma and other locally advanced or metastatic solid tumorssource ↗
●Preclinical PoCPreclinical
Preliminary preclinical studies evaluating DNase I combinations in colorectal cancer models completed
colorectal cancersource ↗
▲Partnership / LicenseCorporate
Extended collaborations with University of Virginia and Scripps Research through 2025
▲Partnership / LicenseCorporate
Entered into Clinical Trial Services Agreement with PeriNess Ltd. for investigator-initiated studies of DNase I
pancreatic carcinoma, colorectal cancer, other solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How XBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-01 | DNase I | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every XBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ErepoXen | anemia in pre-dialysis chronic kidney disease patients | Phase 2 | 2015-07-14 | percentage increase in hemoglobin: 91%; percentage reaching therapeutic range: 75%; therapeutic range: 10-12 g/dLRead More | Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for AnemiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PARSLOW JAMES FOfficer (Interim CEO and CFO) | Grant/Award | 100,000 100,000 held | $0.00 | 04/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in XBIO for Q2 2026. | ||||
XBIO Institutional Ownership Trends
XBIO Short Interest
Shares sold short, counted twice a month.
0.55%
Short % of Float
of tradable shares sold short
11.0K
Shares Sold Short
-14.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
20.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how XBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXBIO News
XBIOXenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Xenetic Biosciences and PeriNess have announced the dosing of the first patient in an investigator-initiated clinical study at Tel Aviv Sourasky University Medical Center. This study evaluates the use of systemic DNase in combination with CAR T-cell therapy for patients with large B-cell lymphoma. Initial efficacy data is anticipated in Q2 2027.
Read more →XBIO▼ -48.7%on this news
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Xenetic Biosciences and Santersus AG have entered a definitive share exchange agreement to form a new company focused on targeting neutrophil extracellular traps (NETs). This merger aims to leverage both companies' technologies, including NucleoCapture® and DNase, to develop therapies for critical care and autoimmune diseases. The combined entity will have four first-in-class clinical programs, including pivotal studies in sepsis and systemic lupus erythematosus, both of which have received FDA Breakthrough Device Designation.
Read more →XBIO▲ +11.2%on this news
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Xenetic Biosciences reported its financial results for Q2 2026, highlighting advancements in its proprietary DNase platform. Positive preclinical data presented at the ASCO meeting showcased the potential of DNase I to enhance CAR T-cell therapies. The company also announced a collaboration with PeriNess Ltd. for a study in large B-cell lymphoma, while generating approximately $1.5 million in royalty revenue.
Read more →XBIOXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Xenetic Biosciences announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory study combining DNase I with anti-CD19 CAR T cells for large B-cell lymphoma patients. The study aims to evaluate the efficacy of this combination therapy, which has shown promising preclinical results, in improving patient outcomes.
Read more →XBIO▲ +5.1%on this newsshared move
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Xenetic Biosciences presented promising preclinical data at ASCO 2026, demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancers. The findings suggest DNase I could be a valuable adjunct therapy to improve outcomes for patients with difficult-to-treat malignancies. The data supports continued clinical development of DNase I in combination with CAR-T therapies.
Read more →XBIO▲ +5.1%on this news
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Xenetic Biosciences reported its Q1 2026 financial results, highlighting a 36% increase in royalty revenue and significant advancements in its DNase oncology platform. The company ended the quarter with $7.3 million in cash and a reduced net loss of $0.5 million. A collaboration partner received approval for a study combining DNase I with CAR T cells in lymphoma, showcasing the platform's potential.
Read more →XBIOXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Xenetic Biosciences, Inc. announced that its abstract has been accepted for presentation at the 2026 ASCO Annual Meeting. The research focuses on a DNase-based therapeutic approach aimed at enhancing CAR T-cell function and improving antitumor responses. The presentation will take place on June 1, 2026, in Chicago, IL.
Read more →XBIO▲ +9.5%on this news· ran to +32% by day 1
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Xenetic Biosciences reported its financial results for 2025, highlighting progress in its DNase-based technology aimed at treating difficult cancers. The company is advancing toward Phase 1 clinical development and has seen increased royalty revenues. However, it also reported a net loss of approximately $2.7 million for the year, reflecting ongoing investments in its scientific programs.
Read more →XBIOXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Xenetic Biosciences, Inc. has announced that its 2025 Annual Meeting of Stockholders was adjourned without any business conducted due to a lack of quorum. The company will reconvene the meeting virtually on January 8, 2026, to allow more time for stockholders to submit their votes. Those who have already submitted their proxies need not vote again, but participation from stockholders who have not yet voted is encouraged to ensure adequate representation.
Read more →XBIOXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Xenetic Biosciences has extended its collaboration with Scripps Research to advance its DNase platform, particularly focusing on the systemic DNase I candidate, XBIO-015. This extension aims to further explore the combination of DNase I with CAR-T cell therapies, which has shown promising results in preclinical studies. The company is preparing for a Phase 1 clinical trial targeting pancreatic carcinoma and other solid tumors.
Read more →XBIOXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Xenetic Biosciences, Inc. has reported its financial results for the third quarter of 2025. The company continues to advance its DNase-based program for cancer treatment while securing $3.9 million from a recent capital offering. Despite a net loss of $0.5 million this quarter, increased revenue and successful partnerships provide a positive outlook for its research efforts. The company is now preparing for Phase 1 clinical trials amid a strategic review process that poses some uncertainties.
Read more →XBIO▼ -33.1%on this news· ran to -49% by day 3
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Xenetic Biosciences, Inc. has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, aiming to raise approximately $4.5 million. The offering is set to close on or around October 14, 2025, subject to customary closing conditions. The proceeds will be allocated for working capital and general corporate purposes. The biotech firm emphasizes its commitment to improving cancer treatments through its innovative DNase platform.
Read more →XBIO▲ +7.2%on this news
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Xenetic Biosciences, Inc. has reported its financial results for Q2 2025, highlighting a significant expansion of its partnership with The Scripps Research Institute. This collaboration aims to advance the program evaluating systemic DNase I combined with CAR T-cell therapies. The company reported a net loss of approximately $0.7 million and reduced research and development costs, showing a focus on efficient operations. With $4.8 million in cash, Xenetic is preparing for Phase 1 clinical trials targeting pancreatic carcinoma and other solid tumors.
Read more →XBIO▼ -7.9%on this news
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences announced a Clinical Study Agreement with PeriNess to explore the use of DNase I in combination with anti-CD19 CAR T therapy for large B cell lymphoma. The study, led by Dr. Ron Ram at the Tel Aviv Sourasky Medical Center, aims to assess the safety and efficacy of this treatment approach. Preliminary data suggests that DNase I may enhance CAR T-cell function and improve patient outcomes.
Read more →XBIOXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences has expanded its collaboration with The Scripps Research Institute to further develop its DNase platform. The research will now include additional lymphoma and leukemia models to validate the efficacy of systemic DNase I combined with CAR T-cell therapies. Promising preclinical data shows that this combination significantly reduces tumor burden and enhances survival rates.
Read more →XBIO▲ +7.7%on this news
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Xenetic Biosciences announced that its collaboration partner, PeriNess, has dosed the first patient in an exploratory clinical study evaluating DNase I in combination with FOLFIRINOX for treating advanced pancreatic cancer. The study aims to assess safety, biomarker response, and clinical activity. This marks a significant step in advancing DNase I technology in oncology.
Read more →XBIOXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2025, highlighting a revenue increase of 16.1% to approximately $0.6 million. The company continues to advance its DNase I development program towards clinical studies for pancreatic carcinoma and has formed a Clinical Study Agreement with PeriNess Ltd. to develop treatments for certain cancers. Despite a reported net loss of approximately $0.9 million, the company's strategic focus on partnerships aims to enhance its technological advancements in immuno-oncology therapies.
Read more →XBIO▲ +5%on this news
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic Biosciences, Inc. has released a Virtual Investor segment featuring Dr. Reid Bissonnette, who discussed promising preclinical data from a recent presentation at the SITC Spring Scientific 2025 Cell Therapy Meeting. The focus was on the company's DNase technology aimed at enhancing CAR-T cell therapy for solid tumors. This technology targets neutrophil extracellular traps involved in cancer progression.
Read more →XBIOXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Xenetic Biosciences announced a Clinical Study Agreement with PeriNess to explore the safety and efficacy of its DNase I candidate, XBIO-015, for treating relapsed/refractory osteosarcoma and Ewing sarcoma. The study will be led by Prof. Ronit Elhasid at the Tel-Aviv Sourasky Medical Center, focusing on the drug's combination with chemotherapy. This initiative aims to improve treatment outcomes for pediatric patients with limited options.
Read more →XBIOCONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address diff
Xenetic Biosciences, Inc. reported its 2024 financial results, highlighting progress in its DNase-based technology for treating difficult cancers. The company has established collaborations with significant partners to further develop its promising therapies, especially for pancreatic carcinoma. Despite a net loss of $4.0 million, Xenetic aims to push forward towards an IND application and Phase 1 clinical trials in 2025. The decrease in research spending could raise concerns about resource allocation, but the overall outlook remains optimistic due to advancements in preclinical data.
Read more →About Xenetic Biosciences, Inc.
Headquarters945 CONCORD ST., FRAMINGHAM, MA, 01701
BIOPHARMAWATCH ELITE PLUS
Trade the next XBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime